Rosiglitazone infusion therapy following minimally invasive surgery for intracerebral hemorrhage evacuation decreases matrix metalloproteinase-9 and blood–brain barrier disruption in rabbits by Guofeng Wu et al.
Wu et al. BMC Neurology  (2015) 15:37 
DOI 10.1186/s12883-015-0287-3RESEARCH ARTICLE Open AccessRosiglitazone infusion therapy following
minimally invasive surgery for intracerebral
hemorrhage evacuation decreases matrix
metalloproteinase-9 and blood–brain
barrier disruption in rabbits
Guofeng Wu1*, Junjie Wu2, Yu Jiao2, Likun Wang1, Fan Wang2 and Yingjun Zhang3Abstract
Background: The objective of this study was to investigate the effects of Rosiglitazone (RSG) infusion therapy
following minimally invasive surgery (MIS) for intracerebral hemorrhage(ICH) evacuation on perihematomal secondary
brain damage as assessed by MMP-9 levels, blood–brain barrier (BBB) permeability and neurological function.
Methods: A total of 40 male rabbits (2.8–3.4 kg) was randomly assigned to a normal control group (NC group; 10 rabbits),
a model control group (MC group; 10 rabbits), a minimally invasive treatment group (MIS group; 10 rabbits) or a combined
MIS and RSG group (MIS + RSG group; 10 rabbits). ICH was induced in all the animals, except for the NC group. MIS was
performed to evacuate ICH 6 hours after the successful preparation of the ICH model in the MIS and MIS + RSG groups. The
animals in the MC group underwent the same procedures for ICH evacuation but without hematoma aspiration, and the NC
group was subjected to sham surgical procedures. The neurological deficit scores (Purdy score) and ICH volumes were
determined on days 1, 3 and 7. All of the animals were sacrificed on day 7, and the perihematomal brain tissue was
removed to determine the levels of PPARγ, MMP-9, BBB permeability and brain water content (BWC).
Results: The Purdy score, perihematomal PPARγ levels, BBB permeability, and BWC were all significantly increased in the MC
group compared to the NC group. After performing the MIS for evacuating the ICH, the Purdy score and the ICH volume
were decreased on days 1, 3 and 7 compared to the MC group. A remarkable decrease in perihematomal levels of PPARγ,
MMP-9, BBB permeability and BWC were observed. The MIS + RSG group displayed a remarkable increase in PPARγ as well
as significant decrease in MMP-9, BBB permeability and BWC compared with the MIS group.
Conclusions: RSG infusion therapy following MIS for ICH treatment might be more efficacious for reducing the levels of
MMP-9 and secondary brain damage than MIS therapy alone.
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Primary intracerebral hemorrhage (ICH) accounts for 10
to 20% of stroke but has the highest rates of mortality
and morbidity of all stroke subtypes [1]. Optimal man-
agement of spontaneous ICH remains one of the highly
debated areas in the field of neurosurgery. Earlier studies
comparing open surgical intervention with optimal medical
management failed to show a clear benefit [2]. Recently re-
ported evidence has shown that surgery is beneficial if it is
performed early before the patient deteriorates [3].
Performing a surgical procedure 6–12 hours after ICH
shows the most significant decrease in MMP-9, BBB
permeability, and neurological deficit score [4]. However,
the role of open surgical management of supratentorial
ICH is still unresolved although decompressive craniect-
omy with hematoma evacuation might be a useful surgical
procedure for selected patients with large hemispheric
hypertensive ICH [5]. Minimally invasive techniques to
evacuate clots appear to be a promising area of research
and warrant further investigation [6]. Currently, minimally
invasive surgery (MIS) is considered as a beneficial treat-
ment for supratentorial spontaneous intracerebral
hemorrhage [7]. MIS for ICH evacuation has been dem-
onstrated to be an effective and safe method in clinical
and experimental studies [8–16]. Patients with supraten-
torial intracerebral hemorrhage may benefit more from
MIS than other treatment options [17]. However, MIS
only reduces the brain damage caused by the hematoma
to some extent and does not completely eliminate the
damage [16]. The roles of MIS in reducing secondary
brain damage remain limited as the erythrocytes and cyto-
toxic substances, which extravasate into the perihemato-
mal brain, are difficult to completely remove. As a result,
MIS to remove ICH followed by medications to prevent
secondary brain damage might be another optimal choice
[18, 19]. MIS plus a recombinant tissue-type plasminogen
activator has achieved favorable results by reducing peri-
hematomal edema [20].
Initial ICH is always followed by secondary brain dam-
age, which is associated with a range of inflammatory
factors, including matrix metalloproteinase-9 (MMP-9),
a member of matrix metalloproteinase family (MMPs).
MMPs have been demonstrated to play an important
role in the disruption of the BBB after ICH [21,22].
MMP-9 participates in the dysregulation of BBB during
hemorrhagic transformation, and it exacerbates brain in-
jury after cerebral ischemia [23]. MMPs are critical for
hematoma and brain edema growth as well as for neur-
onal death in hemorrhagic stroke [24]. MMP-9 may take
part in the secondary injury after ICH, and it is posi-
tively correlated with perihematomal edema volume and
the severity of ICH [25].
Perihematomal edema volume positively correlates
with active MMP-9 and MMP-2 at 24 h and with activeMMP-9 at 48 h [26]. The inhibition of MMP activity
using pharmacological anti-MMP strategies and redu-
cing the release of MMP-9 by MIS for ICH evacuation
may provide an optimal approach for reducing ongoing
edema after ICH [27].
RSG, an agonist of peroxisome proliferator-activated
receptor-gamma (PPARγ), has been demonstrated to be
effective in the treatment of ischemic stroke [28,29].
There are a few studies that have reported the role of
RSG in the treatment of ICH [19,30], thus demonstrat-
ing that RSG promotes hematoma resolution, decreases
neuronal damage, and improves functional recovery.
These findings suggest that the resolution of hematomas
induced by microglia/macrophages activated by PPARγ
is a therapeutic target in ICH treatment [30]. In macro-
phages, PPARγ may act as an important factor in pro-
moting hematoma absorption and protecting other brain
cells from ICH-induced damage [19]. However, there is
little information regarding the role of combining the
MIS and RSG infusion therapy in the treatment of ICH.
Studies have suggested that RSG intervention may
downregulate MMP-9 expression by upregulating PPARγ
expression. Activation of PPARγ in humans limits the ex-
pression of the matrix-degrading MMP-9 [31]. The ad-
ministration of RSG following MIS to treat ICH might be
more efficacious in decreasing the MMP-9 level to reduce
secondary brain damage. Although RSG has been associ-
ated with an increased risk of stroke, the adjusted hazard
ratio for RSG compared to pioglitazone is 1.27 for stroke
[32]. However, the risk of hospital admission for stroke is
not significantly affected by RSG use [33]. PPARγ agonists
have been demonstrated to reduce recurrent stroke and
total events of cardiovascular death or non-fatal stroke.
The present study was designed to assess the effect of
RSG infusion therapy following MIS on perihematomal
secondary brain damage in a rabbit model of ICH.Methods
Main materials
Reagents
The following reagents were used in this study: pre-dyed
protein marker (Fermentas, Ottawa, Canada), x-ray slice
(Shanghai Kodak Company, Shanghai, China), SDS-PAGE
gel kit (Beijing Kangwei Century Biological Technology,
Beijing, China), TEMED (Sigma-Aldrich, California, USA),
Tween 20, bovine serum albumin (BSA; Sigma-Aldrich,
California, USA), 4 x protein sample buffer, beta-
mercaptoethanol (Guiyang Saiweis Biotech Company,
Guiyang City, China), PVDF membrane (Millipore,
Massachusetts, USA), rabbit polyclonal antibody for
PPARγ, rabbit polyclonal antibody for beta-actin (Wuhan
Boster Company, Wuhan, China), and rabbit monoclonal
antibody for MMP-9 (Abcam, Massachusetts, USA).
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ZH-Lanxing B-Type rabbit stereotaxic apparatus (Huaibei
Zhenghua Biological Instrument & Equipment,Xuzhou
City, Jiangsu Province, China), CT provided by the
Guizhou Medical University, G1315 A diode-array de-
tector (DAD, Agilent Technologies, USA), gel-imaging
system (Gene Genius), U-3010 UV–VIS spectropho-
tometer (Hitachi), liquid-removing device (ranges of
100–1000 ml, 20–200 ml, and 0.5-10 ml) (Canada BBI),
and primer design software (Primer Premier 5.0), were
used in this study.
Experimental groups
The present study was approved by the Animal Care
and Use Committee of Guizhou Medical University,
and it was performed according to the criteria of good
laboratory practice for drugs.
Forty male rabbits (2.8–3.4 kg) were provided by the
Experimental Animal Center of Guizhou Medical Uni-
versity. The rabbits were randomly assigned to a normal
control group (NC group; 10 rabbits), a model control
group (MC group; 10 rabbits), a minimally invasive sur-
gery group (MIS group; 10 rabbits) or a combined MIS
and RSG group (MIS + RSG group; 10 rabbits).
Animal preparations
Intracerebral hemorrhage model
The method used to prepare an ICH model was the
same as that used in our previously published studies
[15,16,34]. Briefly, the rabbits were fastened to the
stereotaxic apparatus, and their skulls were drilled.
Using a #12 needle and a 1-ml syringe, 0.5 ml of autolo-
gous arterial blood was taken from the central ear artery.
The syringe was then connected to a #7 needle from
which the tip was removed. The #7 needle was then
inserted vertically and quickly into the skull 12 mm
deep, and the blood was slowly injected into the basalFigure 1 Brain CT showing ICH before and after minimally invasive surgery
successful preparation of the ICH model. B: The ICH was removed after minganglia. A CT scan was performed 3 hours later. High-
density regions in the basal ganglia were indicative of
successful ICH induction (Figure 1A).
The rabbits were housed in the animal room after suc-
cessful ICH induction as confirmed by CT scan. All of
the animals recovered from anesthesia within 5 hours
after intravenous injection of 20% urethane. The total
anesthesia time was 3–5 hours.
The exclusion criteria included visualization of back
flow along the needle track, blood in the ventricle, and
death of the rabbit.Minimally invasive surgery for intracerebral hemorrhage
The rabbits were anesthetized again by injecting 20%
urethane (5 ml/kg) into the ear vein. The rabbits were
then placed in the stereotaxic apparatus, and a #7 nee-
dle was inserted into the hematoma. The liquid part of
the hematoma was aspirated, and 5,000 U of urokinase
(dissolved in 0.5 ml of 0.9% sodium chloride solution)
was injected into the hematoma. The needle was kept
in place for 15 min followed by slow aspiration while
withdrawing the needle. In the MIS + RSG group, RSG
(0.5 mg dissolved in 0.5 ml of 0.9% sodium chloride so-
lution) was infused into the hematoma regions after the
ICH was removed. The procedures performed for the
ICH evacuation were also conducted in the MC group
but without aspirating the hematoma and without
injecting urokinase into the hematoma. The rabbits
were returned to the animal room after surgery.Medical treatment of the animals
The animals in each group received an intramuscular
injection of penicillin (400,000 U) to prevent infection,
and they were housed in the animal until they were
sacrificed. No other medical treatment was administered.. A: The hyper-dense area (the arrow) in the brain CT showing
imally invasive surgery.
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A CT scan was performed on days 1, 3 and 7 to demon-
strate the efficacy of the surgical procedures for ICH
evacuation. The volume of the ICH was calculated be-
fore and after the MIS using the Tada formula as follows:
π/6 × length (cm) × width (cm) × height (cm).
Neurological deficit score measurement
A neurological deficit scale was used to compare the
neurological function among groups [35]. The tests were
conducted on days 1, 3 and 7 by an observer who was
blinded to the treatments.
Brain tissue preparation
All the animals were sacrificed on day 7 after the ICH
model was successfully established. The brain was ex-
tracted and placed on ice. Using the needle track as the
center to prepare a coronal section and a sagittal section,
the brain was cut and divided into the following four
parts on the hematoma side: anterior-inner, anterior-
outside, posterior-inner and posterior-outside. From
each part mentioned above, a total of 5 mm of brain tis-
sue surrounding the hematoma was collected to deter-
mine the PPARγ level, MMP-9 level, EB content and
brain water content (BWC).
Peroxisome proliferator-activated receptor-gamma and
matrix metalloproteinase-9
The brain samples were homogenized in a buffer con-
taining Tris–HCl, NaCl, Triton X-100 and double-
distilled water using a homogenizer. The mixture was
centrifuged at 12000 rpm/min for 15 min at 4°C to isolate
the supernatant. After protein quantification, the samples
were separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto a
polyvinylidene difluoride (PVDF) membrane. The mem-
brane was blocked with blocking buffer overnight at 4°C
and incubated the next day with an anti-PPARγ (1:100)
and anti-MMP-9 antibody (1:500) for one hour at room
temperature followed by incubation with a secondary anti-
body (1:100). Finally, immunoreactive bands were visual-
ized after incubation in a chemiluminescence substrate
and exposure to film. β-actin (1:500) was used as an in-
ternal reference to normalize the results and was probed
using the same procedures as PPARγ and MMP-9. The
densitometric analysis of the bands was conducted using
an image analysis system for Windows (National Institutes
of Health, USA).
Blood–brain barrier permeability measurement
Evans blue (EB) was used as a tracer to measure the
BBB permeability. Two hours before each experiment,
2% EB (2 ml/kg) was injected into the ear vein. After
2 h, the brain tissue was quickly removed. The tissuesurrounding the hematoma was weighed (with an accuracy
of 0.1 mg) and then placed into a test tube with 4 ml of
formamide.
The formamide method was used to measure the EB
content in the brain tissue to gauge the severity of the
BBB damage with the following formula: EB content in
brain tissue (μg/g wet brain) = B × formamide (ml)/wet
weight (g); where B is the EB content of the sample (μg/
ml) given by the linear regression equation according to
a standard curve.
Brain water content measurement
The dry and wet weight method was used to measure
the water content of the brain tissue. The brains were
quickly removed, and a total of 5 mm of brain tissue
surrounding the hematoma was collected. Brain tissues
from the posterior-inner and posterior-outside parts of
the hematoma were used for measuring the BWC. First,
the weight of the wet tissue was obtained. The samples
were placed in an oven at 100°C for 48 h, and the dried
samples were then weighed. The water content of the
brain tissue was calculated as follows: BWC = (wet
weight – dry weight) / wet weight × 100%.
Statistical analysis
All data were analyzed using SPSS 11.5. Basic data are
expressed as the mean ± standard deviation (X ± SD).
ANOVA was used to make comparisons among groups.
A repeated measures ANOVA was used to make com-
parisons across the entire time series. When a difference
was detected by ANOVA, the LSD test was used to
make comparisons between two groups. A p-value less
than 0.05 was considered to be statistically significant.
Statistical analysis was performed in consultation with




Following the infusion of blood into the basal ganglia,
the rabbits manifested with contralateral hemiplegia and
were unable to walk or crawl. Additionally, the contralat-
eral extremities were less responsive to noxious stimula-
tion. The brain CTs showed an oval or round hyperdensity
in the basal ganglia (Figure 1A), demonstrating that the
ICH model in this study was successful and reliable. All
the animals were kept alive until the experiment was ter-
minated. Forty rabbits (each group included 10 rabbits)
were used in the present study.
Intracerebral hemorrhage volume
There were no significant differences in hematoma vol-
ume among the MC (0.475 ± 0.022 ml), MIS (0.478 ±
0.025 ml) and MIS + RGS (0.480 ± 0.028 ml) groups after
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the ICH volume was observed in the MIS and MIS +
RSG groups at each time point (days 1, 3 and 7) com-
pared to the MC group, thus suggesting that the MIS
procedures successfully reduced intracerebral hematoma
(Figures 1B and 2A). A significant difference was also
observed in the ICH volume in the MC group among
the three time points suggesting that the hematoma
could be resolved and absorbed spontaneously.
Functional neurological score
After the model of ICH was successfully established, the
neurological deficit scores of the animals increased sig-
nificantly (8.834 ± 0.753) compared to the normal con-
trol (2.000 ± 0.233) suggesting that the model produced
a neurological deficit. In the MIS and MIS + RSG
groups, the neurological deficit score decreased on days
3 and 7 compared to the MC group (Figure 2B). The
MIS + RSG group displayed more favorable results com-
pared with the MIS group.
Peroxisome proliferator-activated receptor-gamma
PPARγ was expressed in the normal rabbits, and the ex-
pression of PPARγ was significantly increased in the MC
group suggesting that ICH might stimulate the microglia
to increase PPARγ production. A significant difference
was observed among the four groups (F = 108980.96 and
P < 0.01). The LSD analysis demonstrated that the level
of PPARγ protein decreased in the MIS group and in-
creased in the MIS + RSG group compared to the MC
group (P < 0.5). In the MIS group, the quantity of
PPARγprotein was lower than the MIS + RSG group.
These results suggested that the MIS decreased PPARγ
protein expression after the ICH was reduced and that
MIS followed by RSG treatment caused significantFigure 2 ICH volume and the Purdy score changes among different group
aThe ICH volume increased significantly compared to the NC group, P< 0.05; b
significantly compared to the MIS group or MC group, P< 0.05. B: The Purdy sc
increased significantly compared to the NC group, P< 0.05; b Decreased signifi
compared to the MIS group or MC group, P< 0.05.increases in the expression of PPARγ protein compared
with the MC or the MIS group (Figure 3).
Matrix metalloproteinase-9 level
A significant difference in perihematomal MMP-9 levels
was observed among the NC, MC, MIS and MIS + RSG
groups (F = 3236.992 and P < 0.001). MMP-9 was
expressed at low levels in the NC group, and the expres-
sion of MMP-9 was significantly increased in the MC
group. However, the level of perihematomal MMP-9 de-
creased significantly in the MIS and MIS + RSG groups
compared with the MC group (Figure 4). The degree of
decrease of perihematomal MMP-9 was more significant
in the MIS + RSG group compared to the MIS group,
thus suggesting that MIS followed RSG treatment was
more efficacious in facilitating MMP-9 reduction.
Evans blue and brain water content
Both the perihematomal EB (F = 495.501 and P < 0.001)
and the BWC (F = 34.389 and P < 0.001) were signifi-
cantly decreased in the MIS and MIS + RSG groups
compared to the MC group. The MIS + RSG group dis-
played more significant decrease of EB content and the
BWC compared to the MIS group. These results sug-
gested that performing MIS procedures to evacuate the
intracerebral hematoma decreases the EB and the BWC,
and the results also showed that MIS followed by RSG
treatment is more effective in reducing BBB permeability
and cerebral edema (Figures 5-6).
Discussion
In the present study, we utilized an animal model of
ICH to investigate the effects of MIS followed by RSG
treatment on perihematomal PPARγ levels, MMP-9
levels, EB content and BWC. These parameters were all
significantly decreased in the MIS group compared tos. A: The ICH volume changes after minimally invasive surgery (ml, x  s).
Decreased significantly compared to the MC group, P < 0.05; c Decreased
ore changes after minimally invasive surgery (ml, x  s). a The Purdy score
cantly compared to the MC group, P< 0.05; c Decreased significantly
Figure 3 Changes of PPARγ protein expression among different
groups (OD value, x  s).a The PPARγ protein increased significantly
compared to the NC group, P < 0.05; b Decreased significantly in the
MIS group compared to the MC group, P < 0.05; c Increased
significantly compared to the MIS group or MC group, P < 0.05.
Figure 5 Changes of the Evans blue content among different
groups (μg/ml, x  s). a The Evans blue content increased
significantly compared to the NC group, P < 0.05; b Decreased
significantly in the MIS group compared to the MC group, P < 0.05; c
Decreased significantly compared to the MIS group or MC
group, P < 0.05.
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induced effects were obliterated after performing MIS
and that the levels of neurotoxic substances, such as
MMP-9, were reduced. As a result, the perihematomal
inflammatory process was decreased, thus preventing
the need of the microglia or the macrophages to produce
more PPARγ to relieve the inflammatory damages after
ICH. Accordingly, the levels of PPARγ and MMP-9 in
the MIS group were significantly decreased compared to
those of the MC group.
Compared to the MC and MIS groups, the PPARγ
level was the highest in the MIS + RSG group, and the
MMP-9 level, EB content and BWC were the lowest in
the MIS + RSG group. These results demonstrated that
the RSG infusion therapy increased the expression of
PPARγ but decreased the MMP-9 level, EB content and
BWC. RSG infusion therapy following MIS may be more
efficacious in reducing MMP-9 levels and secondary
brain damage than MIS therapy alone. Our previously
published studies have demonstrated that performing
MIS to evacuate ICH reduces the MMP-9 level and sec-
ondary brain damage [15,36]. Other investigators haveFigure 4 Changes of the MMP-9 among different groups
(OD value, x  s). a The MMP-9 increased significantly compared to
the NC group, P < 0.05; b Decreased significantly in the MIS group
compared to the MC group, P < 0.05; c Decreased significantly
compared to the MIS group or MC group, P < 0.05.demonstrated that PPARγ agonists may represent a po-
tential strategy for the treatment of ICH [19]. In the
present study, by combining MIS for ICH evacuation
with PPARγ agonist infusion therapy directed at the ICH
area, we achieved favorable results explained by more
significant decrease of MMP-9 protein as well as the
BBB permeability and the BWC, thus suggesting that
this strategy would be more beneficial than the current
method used for the clinical treatment of ICH.
In recent years, MIS has emerged as an alternative for
traditional craniotomy due to its improved survival rate
and reduced complication rate [37]. However, the utility
of MIS for relieving secondary brain damage is limited
as it cannot remove erythrocytes and cytotoxic sub-
stances, which extravasate into the perihematomal brain.
Recent advances in understanding the pathogenesis of
ICH-induced inflammatory injury have facilitated the
identification of several novel therapeutic targets for the
treatment of ICH. Potential therapies targeting secondary
brain injury have increased interest in translational studies
[38]. Although experimental studies have demonstratedFigure 6 Changes of the BWC among different groups
(%, x  s). a The BWC increased significantly compared to the
NC group, P < 0.05. b Decreased significantly in the MIS group
compared to the MC group, P < 0.05; c Decreased significantly
compared to the MIS group or MC group, P < 0.05.
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achieve favorable results, such strategy is unable to remove
the occupying effect of the ICH. Consequently, performing
MIS to remove the ICH followed by medications to pre-
vent secondary brain damage may be another optimal
choice [18,19].
MMP-9, one of the members of the MMP family, is as-
sociated with the disruption of the BBB and the formation
of brain edema. Intraparenchymal thrombin induces brain
edema formation through MMP-9 expression in rats. Ac-
cordingly, inhibiting the activity MMP-9 or decreasing its
production may provide a potential approach for reducing
ongoing edema after ICH [21]. Our previous studies have
illustrated that MIS for ICH alleviation reduces the levels
of MMP-9 to sufficiently reduce the permeability of the
BBB but is unable to alleviate secondary brain damage
[15,36]. Therefore, new effective therapies are urgently
needed [39]. PPARγ agonists may be a potential strategy
for the treatment of ICH. Intervention with RSG, a PPARγ
agonist, may downregulate MMP-9 expression by upregu-
lating PPARγ expression [40]. Thus, performing MIS for
ICH evacuation followed by the infusion of PPARγ ago-
nists into the hematoma region may be more effective in
the treatment of ICH-induced secondary brain injury,
which was demonstrated in the present study.
In this study, only one dose of RSG was tested. The ef-
fects of RSG at different doses and the side-effects on
the brain were not investigated. Moreover, the sample
size (10 rabbits/group) used in this study was also small.
A further detailed experimental study is required to
demonstrate the efficacy of PPARγ agonists following
MIS for ICH treatment.
Conclusions
The PPARγ level, MMP-9 level, BBB permeability and
BWC increased after the ICH model was established,
and these measurements were significantly decreased
after the ICH was evacuated by MIS. Performing MIS
followed by PPARγ agonist infusion therapy resulted in
an increased PPARγ level and significantly decreased
MMP-9 level, BBB permeability and BWC. Thus, the
combination of the surgical removal of the hematoma
with pharmacological treatment (via local infusion of
RSG) to initiate the endogenous blood absorption mech-
anism to activate PPARγ is an optimal treatment strategy
that is more efficacious for reducing secondary brain
damage and improving neurological function than current
treatment options.
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